BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for Glioblastoma

On April 28, 2026, BioLineRx Ltd. and Hemispherian AS announced that the first patient has been dosed in a Phase 1/2a clinical trial of GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas. GLIX1 is a first-in-class, oral small molecule designed to activate TET2 and induce selective DNA damage in cancer cells. The Phase 1 portion of the study is a dose-escalation monotherapy trial involving up to 30 patients to establish the maximum tolerated dose and safety profile. The study is being conducted at several leading institutions, including NYU Langone Health, Northwestern University, and Moffit Cancer Center. Following the Phase 1 portion, a Phase 2a expansion is planned to explore additional indications, including newly diagnosed GBM and combinations with standard-of-care treatments like PARP inhibitors. GLIX1 has previously demonstrated potent anti-tumor activity and blood-brain-barrier penetration in preclinical models. Initial data from the Phase 1 portion of the trial is anticipated in the first half of 2027.